The purpose of these experiments was to determine the reversibility of a-chaconine and a-solanine inhibition of human plasma butyrylcholinesterase (BuChE). For the substrate a-naphthylacetate, optimal assay conditions were 0.50 M sodium phosphate buffer and a substrate concentration of 3-5 X 10~4 M. Dibucaine (1 X 10~5 M) indicated the usual phenotype for all subjects; achaconine and a-solanine at 2.88 X 10~6 M inhibited BuChE about 70 and 50%, respectively. One-and 24-hr incubations at 1 X 10~! M with a-chaconine, a-solanine, paraoxon, eserine, and ethanol yielded reversible inhibition with dilution except for paraoxon. Twenty-four-hour dialyses of incubations showed no inhibition except for paraoxon. PAGE enzyme activity gels of 1-and 24-hr incubations also showed no inhibition except for paraoxon. aChaconine and a-solanine are reversible inhibitors of human butyrylcholinesterase. At estimated tissue levels, a-chaconine, a-solanine, and solanidine inhibited BuChE 10-86%. In assays which combined a-chaconine, a-solanine, and solanidine, inhibition of BuChE was less than additive. No inhibition of albumin a-naphthylacetate esterase (an arylesterase) was noted with any inhibitor. The importance of these data to adverse toxicological effects of potato alkaloids is diSCUSSed. C 1996 SodMy of Toxicology.
The inhibition of acetylcholinesterase (EC 3.1.1.7) (AChE) and butyrylcholinesterase (BuChE) (also termed pseudo-, serum, or plasma cholinesterase, or simply cholinesterase, EC 3.1.1.8) by alkaloids is considered to be reversible (Dawson, 1990; Goldstein, 1951; Thomsen and Kewitz, 1990) . However, Alozie et al. (1978a) inhibited rat BuChE 49% in vivo with a-chaconine administered ip at 10 mg/kg. After poiyacrylamide gel electrophoresis (PAGE), enzyme activity bands in 10, 30, and 60 mg/kg rats were inhibited to varying degrees. The a-chaconine K, for horse serum cholinesterase was 4 X 10~6 M; for bovine erythrocyte AchE, the K, was 8.3 X 10~6 M. a-Chaconine was classified as a noncompetitive mixed-type inhibitor (Alozie et al., 1978a) .
BuChE is also used to monitor persons exposed to organophosphorus (OP) inhibitors (Gage, 1967; Hayes, 1983) . BuChE is generally more sensitive to OP inhibitors compared to red blood cell AChE (Carter and Maddux, 1974; Grob, 1950; Grob and Harvey, 1949; Grob et al., 1950; Rider et al., 1969) . a-Chaconine and other potato alkaloids also produce OP-type, cholinergic-type symptoms in humans (Hellenas et al., 1992a) . On at least one occasion, human OP poisoning has been diagnosed based on BuChE and AChE depression and symptoms (nausea, vomiting, bradycardia) in the absence of sufficient OP inhibitor to cause either enzyme depression or symptoms (O'Malley and McCurdy, 1990) . Alozie et al.'s (1978a) rat data indicated that potato alkaloid butyrylcholinesterase inhibition was irreversible or partially reversible. Since the Solanaceous plants (tomato, potato, eggplant, peppers) are common in the human diet, the reversible or irreversible inhibition of BuChE from alkaloids found in these foods might lead to a clinical misdiagnosis of OP pesticide poisoning. The experimental data for the reversible inhibition (Dawson, 1990) of human BuChE by a-chaconine and a-solanine does not exist.
There are at least 10 human genetic variants of BuChE (LaDu et al., 1990 (LaDu et al., , 1991 . One of these variants is the atypical response to succinylcholine. Patients homozygous for the variant metabolize succinylcholine slowly, and consequently develop prolonged respiratory paralysis after surgery. Inhibition with dibucaine differentiates the human phenotype for the usual response to succinylcholine from the atypical re-sponse (Kalow and Genest, 1957) . Humans fall into three groups, homozygous (usual), heterozygous, and homozygous (atypical) (Kalow and Staron, 1957) . About 94% of humans are the usual, 3-5% the heterozygous, and 1 in 10,000-30,000 the atypical genotype (Kalow and Staron, 1957; Kalow and Gunn, 1959) . These genotypes may also be differentiated by solanine and solanidine, and as with dibucaine, the atypical and heterozygous genotypes are less inhibited than the usual genotype (Harris and Whittaker, 1962) .
The objectives of this study were to determine if the inhibition of human BuChE by a-chaconine and a-solanine is reversible or irreversible and to examine the inhibition of human BuChE by alkaloid levels expected internally after a potato meal.
METHODS
Serum and plasma. Blood plasma and serum were obtained from anonymous, healthy subjects by the Winter Haven Hospital Clinical Laboratory (Winter Haven, FL). For plasma, blood was collected in EDTA vacuum tubes and the red blood cells separated at 206Og for 10 min. For serum, blood was collected in tubes without coagulant and then allowed to coagulate, and the serum was separated at 2060g for 10 nun. Serum and plasma were stored at -80°C except where noted. Dialysis of plasma and serum was performed with Slide-A-Lyzer dialysis units (Pierce Chemical Co., Inc.), 1 ml of tissue against two 1000-ml changes of buffer at 27°C for 24 hr with magnetic stirring.
Eltctrophoresis conditions and chemicals. Native PAGE was performed using a 6.5% separating gel polymerized with anunonium persulfate and a 4.5% stacking gel polymerized with riboflavin. Electrophoresis was begun within 30 min of stacking gel polymerization. Wells were loaded with 5 /xl of a 0.75:0.25 mixture of serum or plasma and 20% sucrose/ bromophenol blue solution (10 ml 20% sucrose, 1.2 mg bromopheno! blue). The 20% sucrose/bromophenol blue was filtered with a 0.45-/im nylon 66 syringe filter (Gelman) before use. A Bio-Rad minigel unit was used, always with two gels (Bio-Rad, Richmond, CA). Electrophoresis was at 20 mA per gel for 45 min.
After electrophoresis, staining for a-naphthylacetate esterase activity was by a modified method of Gomori (1952) . Gels were placed in 40 ml of either 0.1 or 0.5 M sodium phosphate buffer, pH 7.4, in preliminary experiments, and in 0.5 M sodium phosphate buffer, pH 7.4, in the final experiments. One milliliter of a-naphthylacetate (a-NA) (20 mg/ml in methanol) (Sigma Chemical Co., St. Louis, MO) and 1 ml of Fast Blue BB (5 mg/ ml methanol, filtered with a 0.45-/jm nylon 66 syringe filter) (Sigma Chemical Co., dye content 75%) were added to the incubation buffer while shaking at 100 rpm on a rotary shaker. The staining method of Karnovsky and Roots (1964) with butyrylthiocholine also was used for enzyme activity gels in preliminary experiments.
Inhibitors were prepared as 1.0 mg/ml solutions in absolute ethanol except for a-solanine which was at 0.5 mg/ml. Appropriate quantities were added to incubations for the final concentration. Ethanol was added to incubations to obtain an equal ethanol concentration in each. Formula weights used for calculations were a-chaconine, 852.1; a-solanine, 868.1; solanidine, 397.6; paraoxon, 275.2; and eserine salicylate, 413.5.
Enzyme assays. Assays for total a-naphthylacetate esterase activity were performed at 27°C on a Shimadzu Model V-160 UV-Vis, dual beam recording spectrophotometer at 308 nm. Prior to assays, 6 x 10" 2 M a-NA and 6 X 10~2 M a-naphthol (both in ethanol) and 1 x \0~4 M a-NA and 1 X 10"* M a-naphthol in 0.5 M sodium phosphate buffer, pH 7.4, were scanned from 200 to 800 nm. Both compounds had an absorbance maximum at 308 nm, but a-naphthol had approximately 5x the absorbance compared to a-NA. The reference cell contained 4 X 10~* M a-NA in 20 y\ ethanol and 3 ml of buffer. Assays contained 3.0 ml 0.1 or 0.5 M sodium phosphate buffer, pH 7.4, 25 p\ of plasma or serum, and 4 x 1O~* M a-NA in 20 /il of ethanol. Assays were linear over 200 sec; 100-sec assays with a 10-sec delay were run. The Bio-Rad protein kit with bovine plasma gamma globulin as the standard was used for protein determinations. The diluted BioRad reagent was vacuum-filtered through a 0.45-^m nylon 66 MSI filter before use. Enzyme activity is reported as specific activity (nmol a-NA hydrolyzed/min/mg protein. The dibucaine number (five assays for each patient) (% inhibition by 1 X 10" 3 M dibucaine; Kalow and Genest, 1957 ) was determined on each blood preparation before use except that a-NA was used as the substrate (Alcantara et al., 1991; Simpson and Kalow, 1965) . Additionally, a-solanine and a-chaconine at 2.88 X 10"* M (Hams and Whittaker, 1962) were compared for their ability to determine the human usual phenotype for plasma cholinesterase.
Chemicals. Acylamide, bis-acrylamide, ribofavin, ammonium persulfate, TEMED sucrose, glycine, NaH 2 PO 4 , and NaH 2 PO 4 were electrophoresis grade (Fisher Scientific, Fair Lawn, NJ) . Bromophenol blue, a-NA, anaphthol, a-chaconine (listed purity 95%), a-solanine Qisted purity 95%), solanidine (listed purity 98%), Fast Blue BB, and eserine salicylate were from Sigma Chemical Co. Paraoxon (listed purity 98%) was from Chem Service (Westchester, PA). Absolute alcohol was from AAPER Alcohol and Chemical Co. (Shelbyville, KY). Glass-distilled deionized water was used for all solutions requiring water.
ANOVA (SAS Institute, 1990 ) and Tukey's Honestly Significant Difference (Hochberg and Tamhane, 1987) tests were used to examine statistical differences between inhibitors for each patient. Our statistical analyses only examined the variation of our procedures for one patient. No comparisons were made between patients. Additionally, because of separate blood draws and storage times, various experiments were not compared statistically. The research personnel involved in this study were immunized against hepatitis B, and this study was operated under the Bloodborne Pathogen Guidelines of the University of Florida. This study was approved by the University of Florida Institutional Review Board (human subjects committee).
Preliminary experiments. Enzyme assays and electrophoresis were performed to determine optimum buffer concentration, NaCl activation, and optimum substrate concentration. Three milliliters of serum was incubated with each inhibitor at 27°C for 1 hr in screw cap glass tubes. Alcohol and nonakohol blanks were included. After 1 hr, I-ml aliquots were taken for dialysis, for enzyme assays, and for electrophoresis. Enzyme assays, protein content measurement, and electrophoresis were performed after incubation and also after 24 hr dialysis. The results from the preliminary experiments were used for conditions for a final series of experiments with plasma and serum.
Final experiments. EDTA plasma was prepared from one series of blood draws and serum from a second series of draws, as previously described. A CBC and differential were performed using standard clinical techniques. Aliquots of both serum and plasma were placed at -80°C for later use. The remaining plasma was placed at 4°C; the remaining serum was used immediately. Blood preparations were centrifuged at lOOOg for 20 min before use.
Two milliliters of serum was incubated for 1 hr at 27°C in glass tubes with an incubation concentration of 1 X 10~3 M a-chaconine, a-solanine, paraoxon, eserine, or 30 fi\ of ethanol. The IO~3 M inhibitor concentrations were chosen to guarantee 100% inhibition, particularly for irreversible inhibition. After 1 hr, total enzyme activity assays with a-NA were performed as was PAGE. Nonincubated serum was included as the control. One milliliter of each incubation and 1 ml of nonincubated serum were then dialyzed against 0.5 M, sodium phosphate buffer, pH 7.4, 1000 ml for 8 hr and one 1000-ml change for 16 hr. The remainder of each preparation was left on the benchtop at 27°C for 24 hr, the original serum was placed at -80°C for 24 hr. Total enzyme activity assays at 308 nm contained 3.0 ml 0.5 M Assays contained 30 /xl plasma; means followed by the same letter are not different at a = 0.05 by Tukey's HSD test. Specific activity is nmol a-NA hydrolyzed/min/mg protein.
sodium phosphate buffer, pH 7.4, 25 /il serum, and 20 /A a-NA substrate in ethanol (4 X 10" 4 M assay cone). Four total activity assays were run per sample. Assays were run for 100 sec including a 10-sec delay for a 90-sec rate determination.
RESULTS
The CBC and differential were .within the normal clinical range for all patients. Assays with 0.5 M sodium phosphate buffer had the highest specific activity (data not presented); 0.5 M buffer strength was used for the final experiments although 0.5 M sodium phosphate buffer crystallizes at 4°C. Buffer was consequently held at 27°C and used within 2 days of preparation. There was no apparent NaCl activation in agreement with Alles and Hawes (1940) and Zeller and Bissegger (1943) . The increase in activity with an increase in substrate concentration plateaued from 3 to 5 X 10~4 M a-NA (data not presented). Most enzyme assays had a rate of about 0.0200 nmol/min.
The dibucaine number with time for Patient 1 indicated the usual phenotype (Table 1) (Harris and Whittaker, 1962) . Also, the assays for dibucaine, a-chaconine, and a-solanine inhibition were not different with variable incubation times, in agreement with Kalow and Maykut (1956) (Table 1) . Patients 1, 2, and 3 showed similar inhibition patterns with these inhibitors (Table 2 ), indicating the usual phenotype which is represented in about 94% of the population (Kalow and Gunn, 1959; Kalow and Staron, 1957) . Harris and Whittaker (1962) found 86% inhibition of the usual phenotype by a-solanine at 2.88 X 10" 6 M; we found 50%. Our dibucaine numbers were 68, 71, and 77% compared to about 80% for Harris and Whittaker (1962) (Table 2) . Harris and Whittaker (1962) used benzoylcholine as a substrate. Our use of a-NA as a substrate may account for these differences. Orgell (1963) reported an /50 for solanine of 5 X 10" 6 M at pH 8.2 and 37°C.
For Patient 1, only paraoxon completely inhibited total BuChE activity (Table 3 ). In the experiment in Table 3 , the enzyme assays were run with incubated serum or plasma, consequently diluting the inhibitors (25 fil serum or plasma into 3.0 ml buffer). There was no difference in the specific activity of BuChE comparing a-chaconine, a-solanine, and serum or plasma alone, or serum or plasma with ethanol. After dialysis, the a-chaconine inhibition apparently increased for serum and for plasma (Table 3) . Paraoxon inhibition remained at 100%; eserine inhibition was reversed by dialysis ( Table 3 ). The separate data for the three patients in Table 4 show no inhibition after a 1-hr incubation of serum with 1 X 10" 5 M a-chaconine. a-Chaconine was also diluted 120X in these assays. After dialysis, the activity for Patients 1 and 3 was increased slightly, but the activity for Patient 2 doubled (Table 4) . For the 24-hr incubations, activities increased slightly for serum, but not for serum plus buffer. There was no inhibition by a-chaconine, again with a 120X dilution of a-chaconine in the assay (Table 4) .
Electrophoresis data are not presented and are summarized as follows. Electrophoresis of serum or plasma and staining with a-naphthylacetate or butyrylthiocholin showed the same banding pattern except that the albumin band stained with a-naphthylacetate. The albumin band stained with all inhibitors and is apparently arylesterase activity (Wilde and Kekwick, 1964) . The butyrylthiocholine method (Karnovsky and Roots, 1964) produced smaller bands which took longer to develop. Technique was more critical with the Karnovsky and Roots (1964) method. The a-naphthylacetate method was almost foolproof, but produced fairly high background gels which make poor photographs. Electrophoresis of 1-and 24-hr incubations and dialyzed preparations showed virtually 100% inhibition with paraoxon, no inhibition with a-chaconine and a-solanine, and very slight inhibition with eserine.
The data in Table 5 represent actual concentrations in the assay for solanidine, a-solanine, and a-chaconine for blood concentrations of an alkaloid mixture expected after a potato meal (Hellenas et at, 1992a) . There was no inhibition of plasma cholinesterase at the combined expected blood concentrations (Table 5 ). Single compound estimated tissue concentrations inhibited BuChE 10-86% dependent on inhibitor and concentration (Table 5) . Inhibition was not additive with mixed alkaloids at 5 X 10~7 M each (Table 5) . We speculate that the less than additive inhibition of BuChE by these alkaloids suggests an inhibition which requires binding at two sites by a single compound.
DISCUSSION
There are ample data here to confirm that the enzyme under study was BuChE. Human serum or plasma was used and these contain BuChE and aromatic esterase (Ecobichon and Kalow, 1962) . BuChE is inhibited by both paraoxon and eserine; aromatic esterase is inhibited by neither (Ecobichon and Kalow, 1962) . Inhibition of the a-NA activity of serum or plasma was 100% with paraoxon, about 85-88% with eserine ( Table 3 ). The activity we observed was not activated by NaCl which is characteristic of BuChE; ACHE is NaCl activated (Alles and Hawes, 1940; Zeller and Bissegger, 1943) . The a-NA activity of our preparations reached a plateau with increasing substrate concentration, a characteristic of BuChE; ACHE is inhibited by excess substrate (Glick, 1937; Shafferman et at, 1992; Zeller and Bissegger, 1943) . Although human serum contains two forms of acetylcholinesterase, the activity is very low (Sorensen et at, 1986) and any effect on our experiments appears to be nonexistent. The albumin a-naphthylacetate esterase activity which appeared in electrophoresis gels was not inhibited by paraoxon (data not presented). Since inhibition by paraoxon was 100% in spectrophotometric assays (Table 3) , the albumin activity also had no effect on these experiments. Dawson (1990) defined the criteria for a reversible inhibitor: inhibition reversal with dilution, inhibition independent of time, inhibition reversal with dialysis, and decreased inhibition with increasing substrate concentration (for inhibitors competing with the substrate). At a final concentration of 2.88 X 10~6 M in the actual assay, a-chaconine inhibited plasma cholinesterase 65, 67, and 68%, and a-solanine 42, 46, and 54% (Table 2 ). After incubations, 25 ^1 of serum or plasma were used for a 3.0-ml assay or a final alkaloid concentration of 8.8 X 10~8 M. There was no inhibition in the a-chaconine and a-solanine incubations. Paraoxon inhibition was irreversible; eserine inhibition was reversible. There was a decrease in specific activity after dialysis of 10~5 M a-chaconine serum and plasma with Patient 1 (Table  3) . We have no explanation for this result. The replicated data for three patients in Table 4 showed no inhibition by a-chaconine after dialysis. In Table 4 , the specific activity of 1-hr incubations was the same as 24-hr incubations of a-chaconine. We conclude that BuChE inhibition by these alkaloids is reversible and that consumption of a potato meal would not interfere with a clinical assay for OP intoxication.
After 24 hr dialysis, Patient 2's BuChE activity doubled (Table 4) . This did not occur with 24-hr incubation (Table  4) . We believe this indicates a natural inhibitor of human BuChE, a phenomenon known for other human plasma enzymes (Shirai et al., 1985; Subbaiah et al., 1992) .
The actual concentration of these alkaloids in blood analyses depends on the timing of blood sampling. Claringbold et al. (1980) injected 3 H-solasodine (an aglycone alkaloid in eggplant) into two male, human volunteers. Blood was sampled over 13 days, and urine and feces were sampled for 5 days. Total radiolabel urinary and fecal excretion was 27% of the dose over 5 days. No detectable urinary excretion occurred thereafter. At 8 days, 3.3% of the dose was associated with red blood cells, and 1.6% with plasma (Subject 1). Half-lives in plasma were 8.5 min and 148 hr (Subject 1) and 2.7 min and 83 hr (Subject 2). After 48 hr, 10.6% (Subject 1) and 11.3% (Subject 2) of the dose was in blood. Only about 20% of the dose had been excreted in urine and feces in 48 hr, leaving about 70% of the dose sequestered. With 3 H-solanidine, 90% was sequestered in human volunteers within 24 hr; the excretion half-life was 34-68 days (Claringbold et al., 1982) . Claringbold et al. (1982) also measured solanidine in five postmortem liver samples. Two samples were blank. The positive samples ranged from 79 to 106 /xg/g.
A single oral dose of 0.4 mg/kg a-solanine, 0.6 mg/kg achaconine resulted in maximum serum concentrations of 11.3 ng/ml a-solanine, 14.44 ng/m! a-chaconine, and 4.8 ng/ml solanidine. The serum t j averaged 10.71 hr (a-solanine) and 19.09 hr (a-chaconine) (Hellenas et al., 1992a) . Harvey et al. (1985a,b) measured serum a-solanine in humans just before the noon meal. Assuming Harvey et al.'s (1985a,b) subjects consumed potatoes at lunch and/or dinner, the high value of 36.78 ng/ml (serum) for solanidine should be at least doubled. The blood ratio of solanidine:a-solanine:a-chaconine in the Hellenas et al. (1992a) 1:2.4:4.5. Thus, serum levels could be 73.6 ng/ml solanidine, 176.6 ng/ml a-solanine, and 331.2 ng/ml a-chaconine. These may be theoretically the maximum serum values for these compounds after a potato meal, not considering rapid sequestration. Because of rapid sequestration, blood levels of these alkaloids may not be the important consideration. Assuming regular ingestion of potatoes, these blood concentrations might lead to a liver concentration of 106 /xg/g solanine (2.67 X 10" 4 M) (Claringbold et al., 1982) . Using the ratios above, the a-solanine liver concentration might be 254.4 /xg/ g, and 477 fig/g a-chaconine. These estimated tissue concentrations (2.67 X 10" 4 M solanidine, 2.93 X 10~4 M a-solanine, and 5.60 X 10~4 M a-chaconine) are about 1000X those measured in blood serum. These are very crude estimates, but significant inhibition of BuChE was obtained here at 1/ 100 of these numbers (Tables 1, 2, 5). Based on excretion rate and postmortem samples, Claringbold et al. (1982) estimated a biomagnification of 50X with daily intake of potatoes, an estimate refuted by their own postmortem data discussed above.
Unfortunately, relative tissue concentrations of these alkaloids have not been studied in humans. The excretion of achaconine and a-solanine in the rat is different from that in man (Norred et al., 1976) ; hamster excretion of a-solanine is comparable to human excretion of this compound (Alozie et al., 1979; Claringbold et al., 1980; Groen et al., 1993) . Oral administration of 10 mg/kg 3 H-a-chaconine to the hamster led to bound residues in lung, liver, kidney, heart, brain, and testes. Residues in brain and testes were 100% bound (Alozie et al., 1978b) .
The human placenta contains BuChE which may be protective against alkaloids; some alkaloids are metabolized by this enzyme, e.g., cocaine (Roe et al., 1990; Simone et al., 1994) . Cocaine toxicity was enhanced in mice by lower butyrylcholinesterase activity (Hoffman et al., 1992) . Placental butyrylcholinesterase activity appears to be due to maternal blood (Ruch et al., 1976) , but a genetic variant unique to the placenta may exist (Bell et al., 1979; Singh et al., 1992a,b) . Recent, careful experiments indicate that human placenta contains both BuChE and AChE activity (Si-mone et ai, 1994) . However, BuChE mRNA was not detected in human placenta (Jbilo et ai, 1994) . BuChE in the newbom is about 50% of a healthy nonpregnant adult (Ecobichon and Stephens, 1972) . Cord BuChE activity may be greater than the mother and maternal BuChE activity is reduced about 20% in the first trimester (Kalow and Gunn, 1959; Whittaker, 1986) . Maternal blood BuChE activity is reduced during puerperium. Activity returns to normal 3-6 weeks postpartum. BuChE activity in juveniles increases over Years 3-5 and falls to the adult level at puberty (Whittaker, 1986) .
The alkaloids in potatoes have been associated epidemiologically with human spina bifida and anencephaly (Leek and Record, 1966; Renwick, 1972a Renwick, ,b, 1973 , a supposition which was immediately challenged (Nevin and Merrett, 1975) . Potatoes and individual alkaloids have been shown to be teratogenic, embryotoxic, and toxic to the mother, and to cause excess resorption in rats, mice, and hamsters (Baker et ai, 1987; Chaube and Swinyard, 1976; Keeler, 1973; Keeler et ai, 1978 Keeler et ai, , 1990 Pierre et ai, 1977; Poswillo et ai, 1972 Poswillo et ai, , 1973 Renwick et ai, 1984; Swinyard and Chaube, 1973) . Solanine or mixed alkaloids were teratogenic to the chicken embryo (Mun et ai, 1975) . Solanine was abortifacient in mice and this effect was synergized by aspirin (Bell et ai, 1976) . Concentration-dependent teratogenic responses were obtained with a-chaconine, a-solanine, solasodine, and a-tomatine in the frog embryo {Xenopus) assay (Friedman et ai, 1992) . The rat appears to be resistant to the teratogenic effect of these alkaloids (Hellenas et ai, 1992b) .
a-Chaconine, a-solanine, and solanidine were not genotoxic in the Ames test and mouse micronucleus tests (Friedman and Henika, 1992; Ness et ai, 1984) . Solanine noncompetitively inhibited calcium transport in vivo (5 mM in drinking water = 4.34 mg/ml suspension) in rat duodenum (Michalska et ai, 1985) . Either a-chaconine or a-solanine reduced sodium ion active transport at 10 mg/1 in frog skin, a mechanism which has been suggested for these alkaloids' embryotoxic and teratogenic effects (Blankemeyer et ai, 1995) . The early ontogenetic appearance of cholinesterases and their relationship to neurogenesis have been reviewed (Karczmar, 1963 (Karczmar, , 1993 . BuChE levels have been correlated with cell proliferation in the brain and retina in the chick (Layer and Sporns, 1987) and BuChE inhibition reduced AChE gene expression (Layer, 1991) . We suggest that the BuChE inhibition we observed at expected (sequestered) human tissue levels is possible as a teratogenic mechanism of Solanaceous alkaloids.
The level of alkaloids in potatoes is increased by a variety of factors such as light, disease, mechanical injury, physiological condition, genetics, storage, insect damage, and chemicals (Ahmed and MUller, 1978; Cronk et ai, 1974; Fitzpatrick et ai, 1977; Gregory et ai, 1981; Hlywka et ai, 1994; Jadhav and Salunkhe, 1975; Osman et ai, 1978; Percival et ai, 1996; Sinden et ai, 1984) . Neither a-chaconine nor a-solanine levels are affected by food processing and preparation (Bushway and Ponnampalam, 1981; Zhao et ai, 1994) . Potato alkaloids are highest in sprouts > peel > flesh (Friedman and Dao, 1992) . There are no tolerances for alkaloids in potatoes, only a taste standard set at 200 ppm total alkaloid (Zitnak and Filadelfi, 1985) . The human oral lethal dose of a-chaconine was estimated to range from 3 to 6 mg/kg (strychnine = 5 mg/kg) (Morris and Lee, 1984) . Prisoners fed 2 mg/kg a-solanine produced classical symptoms of glycoalkaloid poisoning (Morris and Lee, 1984) . Six of the seven volunteers ingesting 1 mg/kg (0.4 mg/kg asolanine + 0.6 mg/kg a-chaconine) reported light to severe nausea (one case of diarrhea) within 30 min of ingestion and lasting 3-4 hr (Hellenas et ai, 1992a) . It is a matter of simple calculation to determine that a 70-kg person consuming a 250-g potato at the 200 mg/kg taste standard potentially may ingest 11% of the estimated lethal dose of 6 mg/kg. That is, 50 mg/70 kg = 0.714 mg/kg. The 200 mg/kg total alkaloid taste "standard" for potato consequently has a zero safety tolerance. Most potato varieties contain 100 mg/kg or less in the peel and less in the flesh (Jadhav and Salunkhe, 1975) , but some varieties are high in glycoalkaloids (Sinden et ai, 1984) and commercial varieties may be well above 200 mg/kg dependent on handling after harvest (Ahmed and MUller, 1978; Percival et ai, 1996) . The variety Lenape with a glycoalkaloid content of 270 mg/kg or more was withdrawn from the market in 1970 after consumer complaints (Sinden et ai, 1984) .
Atypical BuChE is resistant and intermediate BuChE somewhat resistant to inhibition by a-chaconine, a-solanine, and a variety of other inhibitors (Harris and Whittaker, 1962; Kalow and Davies, 1958; Kalow and Maykut, 1956) . We suggest that the study of the onset of acute gastrointestinal symptoms in usual, intermediate, atypical, or silent phenotypic individuals after a potato meal would be an appropriate double-blind study. The BuChE phenotype of spina bifida mothers should be determined. Also, the inhibition of placental and fetal esterase(s) by Solanaceous alkaloids should be investigated, as should their sequestration in adult and fetal tissues. We recommend that a systematic study of the embryotoxicity and teratogenicity of Solanaceous alkaloids be conducted with the goal of setting a toxicologically based standard for human consumption.
